SEBI Reg. Investment Advisor

Download App

Help Center Pricing

Recent:

Top Pharma Companies in India by Market Cap

BSE Sensex 76913.50
582.86 (-0.75%)

Filter

Top Pharma Companies in India as on May-2026 | 5 Star Rated Stocks Undervalued Stocks Fair Valued Stocks Uptrend Stocks

Filter

	Company Name	DeciZen	Market cap (Rs. Cr.)	CMP (Change %)	Latest P/E	Latest P/BV	5Y Sales Gr.(%)	5Y Profit Gr.(%)
31	Sun Pharmaceutical Industries Ltd.	Q V+ PT	4,33,848 Large Cap	1,808.20 (1.64%)	39.1	5.26	9.87	23.50	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
32	Akums Drugs & Pharmaceuticals Ltd.	Q V PT	8,616 Small Cap	547.40 (0.78%)	68.92	3.56	12.22	23.36	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
33	Dr. Reddys Laboratories Ltd.	Q V PT	1,10,421 Mid Cap	1,322.95 (-0.54%)	19.94	2.98	13.26	22.29	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
34	Innova Captab Ltd.	Q V PT	4,298 Small Cap	751.10 (2.78%)	52.5	4.77	20.74	22.12	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
35	Syncom Formulations (India) Ltd.	Q V PT	1,291 Small Cap	13.73 (-0.29%)	18.78	3.27	17.63	21.67	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
36	Caplin Point Laboratories Ltd.	Q V PT	13,003 Small Cap	1,710.60 (-0.88%)	21.37	3.94	17.55	21.52	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
37	Anuh Pharma Ltd.	Q V PT	822 Small Cap	81.99 (-0.13%)	19.68	2.42	16.60	20.73	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
38	Shree Ganesh Remedies Ltd.	Q V PT	661 Small Cap	514.65 (2.72%)	35.53	4.11	13.20	20.49	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
39	Astrazeneca Pharma India Ltd.	Q V+ PT	20,543 Small Cap	8,217.20 (-1.95%)	104.3	25.2	15.59	20.47	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
40	JB Chemicals & Pharmaceuticals Ltd.	Q V+ PT	32,884 Small Cap	2,048.10 (-0.72%)	45.54	8.49	17.81	19.45	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
41	Morepen Laboratories Ltd.	Q V+ PT	2,269 Small Cap	41.41 (-0.96%)	39.61	1.88	14.44	19.03	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
42	Abbott India Ltd.	Q V PT	54,039 Mid Cap	25,430.90 (-0.21%)	35.53	12.34	9.38	18.78	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
43	Vijaya Diagnostic Centre Ltd.	Q V PT	10,897 Small Cap	1,126.95 (1.27%)	67.49	11.86	15.00	18.43	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
44	Supriya Lifescience Ltd.	Q V PT	5,590 Small Cap	694.50 (-0.72%)	30.39	4.98	17.45	18.30	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
45	Concord Biotech Ltd.	Q V PT	11,928 Small Cap	1,140.15 (0.73%)	37.89	6.26	18.56	18.12	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
46	Dr. Lal Pathlabs Ltd.	Q V PT	22,935 Small Cap	1,368.10 (-2.10%)	45.42	9.3	13.05	17.98	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
47	Windlas Biotech Ltd.	Q V PT	1,800 Small Cap	852.70 (0.05%)	26.97	3.28	18.24	17.22	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
48	Kovai Medical Center & Hospital Ltd.	Q V+ PT	6,199 Small Cap	5,665.45 (-0.65%)	26.46	4.97	14.01	17.17	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
49	Ajanta Pharma Ltd.	Q V PT	35,289 Small Cap	2,824.60 (0.70%)	34.54	7.64	12.43	17.07	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
50	Krishna Institute of Medical Sciences Ltd	Q V PT	26,651 Small Cap	666.05 (0.11%)	92.35	11.27	11.87	17.04	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
51	Acutaas Chemicals Ltd.	Q V+ PT	21,258 Small Cap	2,596.55 (3.84%)	70.12	13.4	32.80	16.82	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
52	Gujarat Themis Biosyn Ltd.	Q V+ PT	3,964 Small Cap	363.75 (-3.22%)	85.7	14.79	12.12	15.55	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
53	Torrent Pharmaceuticals Ltd.	Q V+ PT	1,41,859 Large Cap	4,191.50 (-0.91%)	63.01	15.76	7.72	15.29	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
54	SMS Pharmaceuticals Ltd.	Q V+ PT	3,789 Small Cap	404.55 (-1.28%)	43.96	4.9	13.70	14.47	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
55	Glenmark Pharmaceuticals Ltd.	Q V+ PT	67,885 Mid Cap	2,405.55 (-0.21%)	63.87	6.81	4.60	14.41	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
56	Kopran Ltd.	Q V PT	795 Small Cap	164.70 (5.14%)	37.35	1.77	8.61	14.34	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
57	Mankind Pharma Ltd.	Q V PT	92,744 Mid Cap	2,246.55 (-0.36%)	54.64	5.83	14.65	12.79	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
58	KMC Speciality Hospitals (India) Ltd.	Q V PT	1,430 Small Cap	87.70 (0.15%)	N/A	N/A	19.21	12.72	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
59	Procter & Gamble Health Ltd.	Q V PT	8,623 Small Cap	5,194.55 (1.33%)	28.99	12.2	4.31	11.97	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
60	Advanced Enzyme Technologies Ltd.	Q V PT	3,894 Small Cap	347.95 (3.23%)	31.29	5.51	7.28	11.87	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
Prev 1 2 3 4 5 Next

Screens:

AlphaCases Top Rated Stocks Best Nifty Stocks Best Nifty Next Stocks Best Nifty 500 Stocks Best SmallCap Stocks Top BFSI Stocks

Pharma - Today's Top Gainers

Company Name	CMP	Price Change(%)
RPG Life Sciences	2,297.45	13.59%
Syngene Internation.	467.90	8.30%
Guj. Kidney & Super	125.40	5.38%
Kopran	164.70	5.14%
Aarti Pharmalabs	744.25	4.91%

Pharma - Today's Top Losers

Company Name	CMP	Price Change(%)
3B Blackbio Dx	1,206.60	-4.77%
Lincoln Pharma	645.40	-4.19%
Sun Pharma Adv. Res	142.85	-3.71%
Laxmi Denta	199	-3.40%
Guj. Themis Biosyn	363.75	-3.22%

News about Top Pharma Companies in India

May, 2026

SMS Pharmaceuticals informs about newspaper publication

SMS Pharmaceuticals has enclosed copies of the newspaper advertisements published today in the the Financial Express (English), and in Nava Telangana (Telugu), informing about the Investor Education and Protection Fund Authority’s (IEPFA) ‘Second 100-Days CampaignSaksham Niveshak’. This information is also being uploaded on the Company’s website at www.smspharma.com

The above information is a part of company’s filings submitted to BSE.

May, 2026

Dr. Lal PathLabs informs about update on acquisition

In continuation to its earlier intimation dated April 30, 2026 with respect to acquisition of 100% stake in Shahbazkers Diagnostic Centre (‘SDCPL’) and pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, Dr. Lal PathLabs has informed that the Company has completed the said acquisition on May 01, 2026 as per the terms and conditions of the Share Purchase Agreement. Pursuant to completion of said acquisition, SDCPL has now become Wholly Owned Subsidiary of the Company. The disclosure(s) as required under Regulation 30 of the Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 as amended from time to time, have already been duly intimated in the earlier intimation dated April 30, 2026.

The above information is a part of company’s filings submitted to BSE.

May, 2026

Dr. Lal Pathlabs - Quaterly Results

The revenue zoomed 16.98% to Rs. 6752.00 millions for the quarter ended March 2026 as compared to Rs. 5772.00 millions during the corresponding quarter last year.The Net Profit of the company registered a slight decline of -4.92% to Rs. 1411.00 millions from Rs. 1484.00 millions.Operating profit surged to 2185.00 millions from the corresponding previous quarter of 1843.00 millions.

(Rs. in Million)

	Quarter ended			Year to Date			Year ended
	202603	202503	% Var	202603	202503	% Var	202603	202503	% Var
Sales	6752.00	5772.00	16.98	26476.00	23516.00	12.59	26476.00	23516.00	12.59
Other Income	370.00	252.00	46.83	1127.00	1115.00	1.08	1127.00	1115.00	1.08
PBIDT	2185.00	1843.00	18.56	8664.00	7770.00	11.51	8664.00	7770.00	11.51
Interest	59.00	48.00	22.92	220.00	215.00	2.33	220.00	215.00	2.33
PBDT	2126.00	1795.00	18.44	8143.00	7555.00	7.78	8143.00	7555.00	7.78
Depreciation	427.00	346.00	23.41	1541.00	1342.00	14.83	1541.00	1342.00	14.83
PBT	1699.00	1449.00	17.25	6602.00	6213.00	6.26	6602.00	6213.00	6.26
TAX	288.00	-35.00	-922.86	1520.00	1240.00	22.58	1520.00	1240.00	22.58
Deferred Tax	15.00	-415.00	-103.61	14.00	-393.00	-103.56	14.00	-393.00	-103.56
PAT	1411.00	1484.00	-4.92	5082.00	4973.00	2.19	5082.00	4973.00	2.19
Equity	1676.00	836.00	100.48	1676.00	836.00	100.48	1676.00	836.00	100.48
PBIDTM(%)	32.36	31.93	1.35	32.72	33.04	-0.96	32.72	33.04	-0.96

May, 2026

Acutaas Chemicals - Quaterly Results

The sales surged to Rs. 4217.72 millions, up 38.67% for the March 2026 quarter as against Rs. 3041.61 millions during the corresponding quarter previous year.The Net Profit of the company vaulted to 118.10% to Rs. 1370.71 millions from Rs. 628.48 millions in the previous quarter.Operating Profit saw a handsome growth to 1957.63 millions from 897.52 millions in the quarter ended March 2026.

(Rs. in Million)

	Quarter ended			Year to Date			Year ended
	202603	202503	% Var	202603	202503	% Var	202603	202503	% Var
Sales	4217.72	3041.61	38.67	13237.92	9898.35	33.74	13237.92	9898.35	33.74
Other Income	145.46	56.94	155.46	458.78	183.36	150.21	458.78	183.36	150.21
PBIDT	1957.63	897.52	118.12	5288.83	2434.78	117.22	5288.83	2434.78	117.22
Interest	10.72	3.83	179.90	30.77	58.57	-47.46	30.77	58.57	-47.46
PBDT	1946.91	893.69	117.85	5258.06	2376.21	121.28	5258.06	2376.21	121.28
Depreciation	88.30	65.56	34.69	330.32	240.45	37.38	330.32	240.45	37.38
PBT	1858.61	828.13	124.43	4927.74	2135.76	130.73	4927.74	2135.76	130.73
TAX	487.90	199.65	144.38	1265.99	540.29	134.32	1265.99	540.29	134.32
Deferred Tax	17.36	47.36	-63.34	111.09	70.58	57.40	111.09	70.58	57.40
PAT	1370.71	628.48	118.10	3661.75	1595.47	129.51	3661.75	1595.47	129.51
Equity	409.36	409.34	0.00	409.36	409.34	0.00	409.36	409.34	0.00
PBIDTM(%)	46.41	29.51	57.29	39.95	24.60	62.42	39.95	24.60	62.42

Apr, 2026

Dr. Reddy's Lab gets Health Canada’s nod for Generic Semaglutide Injection

The company becomes the first company to receive the market authorization for generic Semaglutide Injection in Canada

Apr, 2026

Dr. Reddy’s Laboratories informs about updates

Dr. Reddy’s Laboratories has informed that the company (‘Dr. Reddy’s’) has on April 29, 2026, received a Notice of Compliance (i.e. an approval) from the Pharmaceutical Drugs Directorate, Canada (‘Health Canada’) regarding its Abbreviated New Drug Submission (ANDS) of Semaglutide Injection. The relevant details as required under Regulation 30 of the SEBI Listing Regulations read with the SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, are enclosed. A press release being issued in relation to the above matter is also enclosed.

The above information is a part of company’s filings submitted to BSE.

Top 10 Publicly Listed pharmaceutical stocks in India by Market Capitalization as of 2026.

Rank	Company	Market Capitalization 2026 (INR crores)
1	Yatharth Hospital & Trauma Care Services Ltd.	7,894 Crore
2	3B Blackbio Dx Ltd.	1,036 Crore
3	Neuland Laboratories Ltd.	19,243 Crore
4	Vimta Labs Ltd.	2,043 Crore
5	Max Healthcare Institute Ltd.	96,657 Crore
6	Novartis India Ltd.	2,550 Crore
7	Narayana Hrudayalaya Ltd.	36,093 Crore
8	Anthem Biosciences Ltd.	42,676 Crore
9	Jagsonpal Pharmaceuticals Ltd.	1,412 Crore
10	Kwality Pharmaceuticals Ltd.	1,641 Crore

Do you know? Asking 3 Right Questions minimizes the RISK of Stock Investing To Know

Right Stock | Right Price | Right Allocation

Find best stocks to buy now Find best pharma stocks to buy now

Top 15 Pharma Stocks by Revenue Growth

Top Pharma Companies Source: NSE Indices

You can use different criterias to arrive at the list of best stocks in the Nifty Pharma company index. You can use return ratios like ROCE or ROE, that will help you choose companies with profitable growth.

Based on ROE, the best stocks in the Nifty Pharma companies index are:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	ROE
Abbott India Ltd. (M)	Very Good	25,431	54,039	35.46	12.32	24.79	35.71
Torrent Pharmaceuticals Ltd. (L)	Very Good	4,192	1,41,859	62.44	15.62	35.30	26.68
Ajanta Pharma Ltd. (S)	Very Good	2,825	35,289	34.78	7.69	23.80	24.45
Lupin Ltd. (M)	Somewhat Good	2,304	1,05,320	22.67	5.06	13.52	20.83
Zydus Lifesciences Ltd. (M)	Very Good	892	89,721	18.17	3.42	11.35	20.74

Based on the past year's gain, the best performing stocks are:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	Yearly gain (%)
No Yearly Gainers for this list.				View More

Stocks with the highest revenue growth in the past 5 years is:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	5Y Sales Growth (%)
JB Chemicals & Pharmaceuticals Ltd. (S)	Very Good	2,048	32,884	45.21	8.43	28.55	17.81
Mankind Pharma Ltd. (M)	Very Good	2,247	92,744	54.44	5.81	32.80	14.65
Laurus Labs Ltd. (M)	Very Good	1,099	59,336	66.76	11.20	33.62	14.42
Dr. Reddys Laboratories Ltd. (M)	Very Good	1,323	1,10,421	19.83	2.97	11.91	13.26
Ajanta Pharma Ltd. (S)	Very Good	2,825	35,289	34.78	7.69	23.80	12.43

Stocks with high profit growth often witness their stock prices gaining, irrespective of the market movements.

Stocks with the highest profit growth in the past 5 years is:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	5Y Profit Growth (%)
Zydus Lifesciences Ltd. (M)	Very Good	892	89,721	18.17	3.42	11.35	30.57
Cipla Ltd. (L)	Very Good	1,310	1,05,811	23.27	3.15	14.04	30.14
Sun Pharmaceutical Industries Ltd. (L)	Very Good	1,808	4,33,848	39.75	5.34	21.73	23.50
Dr. Reddys Laboratories Ltd. (M)	Very Good	1,323	1,10,421	19.83	2.97	11.91	22.29
JB Chemicals & Pharmaceuticals Ltd. (S)	Very Good	2,048	32,884	45.21	8.43	28.55	19.45

You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login | Register Now

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Fiduciary-first advisory model.
As SEBI-registered IAs, we are legally and ethically bound to act in the best interests of our clients. We do not sell or distribute any financial products. This ensures our guidance is 100% unbiased and conflict-free.
Deep fundamental research + robust valuation discipline.
Built on more than 15 years of equity research, our framework combines quality assessment, intrinsic value estimation, and a sensible margin-of-safety approach.
Process—not predictions.
We don’t rely on guesswork or market timing. Instead, we focus on asset allocation, risk management, and long-term compounding.
Technology + Human Intelligence.
We believe a combination of both is essential for investing success. We constantly innovate and upgrade in-house tools, financial X-rays, and portfolio analytics so that our team of analysts and advisors are equipped with the best.
Partner with Clients.
We follow a DIWM (Do-It-With-Me) approach where we partner clients in setting goals, financial planning, educating on our investing process and share decision-enabling resources transparently with our clients who retain control on execution.

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

Investing in stocks, mutual funds, debt, and gold
Quality-at-Reasonable-Price way of investing in stocks
Constructing Direct Stock Portfolios with Core, Booster, and Amplifier stocks
A Mutual Fund Portfolio that delivers consistent out-performance and meaningful diversification (low overlap)
Periodic review and rebalancing
Clear Buy-Sell-Hold, and Position-sizing frameworks

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Top Pharma Companies in India by Market Cap

News about Top Pharma Companies in India

SMS Pharmaceuticals informs about newspaper publication

Dr. Lal PathLabs informs about update on acquisition

Dr. Lal Pathlabs - Quaterly Results

Acutaas Chemicals - Quaterly Results

Dr. Reddy's Lab gets Health Canada’s nod for Generic Semaglutide Injection

Dr. Reddy’s Laboratories informs about updates

Publicly traded pharmaceuticals

Top 10 Publicly Listed pharmaceutical stocks in India by Market Capitalization as of 2026.

Top 15 Pharma Stocks by Revenue Growth

Top Pharma Companies Source: NSE Indices

How to select the top Nifty Pharma stocks based on RoE?

What are the best-performing stocks in the Nifty Pharma index?

Which Nifty Pharma stocks have the highest revenue growth in the past five years?

Which Nifty Pharma stocks had the highest profit growth in the past five years ?

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.